During prism adaptation (PA), active exposure to an optical shift results in sustained modifications of the sensorimotor system, which have been shown to expand to the cognitive level and serve as a rehabilitation technique for spatial cognition disorders. Several models based on evidence from clinical and neuroimaging studies offered a description of the cognitive and the neural correlates of PA. However, recent findings using noninvasive neurostimulation call for a reexamination of the role of the primary motor cortex (M1) in PA. Specifically, recent studies demonstrated that M1 stimulation reactivates previously vanished sensorimotor changes 1 day after PA, induces after-effect strengthening, and boosts therapeutic effects up to the point of reversing treatment-resistant unilateral neglect. Here, we articulate findings from clinical, neuroimaging, and noninvasive brain stimulation studies to show that M1 contributes to acquiring and storing PA, by means of persisting latent changes after the behavioral training is terminated, consistent with studies on other sensorimotor adaptation procedures. Moreover, we describe the hierarchical organization as well as the timing of PA mechanisms and their anatomical correlates, and identify M1 as an anatomo-functional interface between low- and high-order PA-related mechanisms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1162/jocn_a_01668 | DOI Listing |
Alzheimers Dement
December 2024
Centre for Brain Research, Indian Institute of Science, Bangalore, Karnataka, India.
Background: Worsening pulmonary health may be independently associated with declining cognitive function. However, the association between specific types of pulmonary impairment with cognitive function is not well understood. The present study aims to determine the differential impact of Chronic Obstructive Pulmonary Disease (COPD) and Preserved Ratio Impaired Spirometry (PRISm) in a rural Indian aging cohort METHOD: Data from participants (n = 1223) of the Srinivaspura Aging, Neuro Senescence and COGnition (SANSCOG) cohort were analyzed.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Primary care clinicians report limited self-efficacy for managing complex behavioral and psychological symptoms in persons with dementia (BPSD). Complementary approaches, the academic detailing model and the DICE Approach, improved self-efficacy for memory clinic clinicians and their teams to identify and manage BPSD. Methods guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) / PRISM (Practical, Robust, Implementation and Sustainability Model) framework are shared for pre-implementation adaptation of this program for generalist primary care.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Queensland, Brisbane, QLD, Australia.
Background: Dementia is highly stigmatised, misperceived as a mental illness, and considered a normal part of ageing by people from culturally and linguistically diverse backgrounds in Australia. There is a lack of valid and reliable scale to measure their dementia attitudes. This study aimed to cross-culturally translate and validate a dementia attitudes scale in Arabic, Vietnamese, Chinese, and Greek communities as they represent the main languages spoken throughout Western Sydney, Australia.
View Article and Find Full Text PDFNat Commun
January 2025
Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.
View Article and Find Full Text PDFFundam Clin Pharmacol
February 2025
PRISM Biogénopôle La Timone University Hospital of Marseille, APHM, Marseille, France.
Background: Imatinib is the treatment of elderly or frail patients with chronic myeloid leukemia (CML). Trough levels of around 1000 ng/ml are considered as the target exposure.
Objectives: We searched for baseline parameters associated with imatinib pharmacokinetics, and studied the clinical impact of subsequent adaptive dosing.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!